Oculis Holding AG (OCS)
OCS moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How OCS actually reacts to news — the realized, point-in-time move the market made, measured across 322 labeled events over the last three years with zero look-ahead.
OCS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 293 |
| 30-min | 0.00% | 47% | 310 |
| 60-min | -0.08% | 47% | 315 |
| to close | 0.00% | 48% | 317 |
| Middle 50% of OCS reactions | -0.97% to +0.80% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 322 |
Half of all Oculis Holding AG news events land between -0.97% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OCS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | -0.15% | 50% | +0.98% |
| Rating reiterations | 67 | -0.11% | 36% | -0.51% |
| Price-target raises | 16 | 0.00% | 44% | -0.28% |
| Price-target cuts | 11 | +0.08% | 55% | -0.39% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OCS ranks against every other measured name →
That’s how OCS usually reacts — get an email when it moves on news →Email me when OCS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OCS's baseline. Nothing else.
Recent OCS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease | Press release | GlobeNewswire | +0.00% | +0.97% | |
| Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day | Press release | GlobeNewswire | -3.17% | -3.74% | |
| Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS | Press release | GlobeNewswire | +0.22% | -4.37% | |
| Form 6-K Oculis Holding AG For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +0.22% | -4.37% | |
| First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis | Press release | GlobeNewswire | -1.07% | +0.61% | |
| Form 6-K Oculis Holding AG For: Aug 10 | SEC filing · Form 6-K | SEC EDGAR | +2.52% | — | |
| Form 6-K Oculis Holding AG For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +2.22% | +0.64% | |
| Form S-8 Oculis Holding AG | SEC filing · Form S-8 | SEC EDGAR | +2.22% | +0.64% | |
| Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference | Press release | GlobeNewswire | +1.60% | +2.92% | |
| Form 6-K Oculis Holding AG For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | +2.65% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.18% | +2.23% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.09% | +3.06% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.50% | +0.96% | |
| Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | -0.04% | |
| Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 | Press release | GlobeNewswire | +0.23% | +0.73% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.39% | -4.40% | |
| Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease | Press release | GlobeNewswire | -0.73% | +0.09% | |
| Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | -4.38% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -1.07% | -4.15% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.40% | -5.13% | |
| Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +1.12% | +4.95% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.43% | -2.69% | |
| OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations | Press release | PR Newswire | -3.64% | -12.21% | |
| Form 6-K Oculis Holding AG For: May 29 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -8.05% | |
| Form 6-K Oculis Holding AG For: May 14 | SEC filing · Form 6-K | SEC EDGAR | +1.77% | +1.34% | |
| Form 6-K Oculis Holding AG For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.56% | -5.41% | |
| Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial | Press release | GlobeNewswire | -3.87% | +0.29% | |
| Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Press release | GlobeNewswire | +0.38% | +0.00% | |
| Form 6-K Oculis Holding AG For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | +0.55% | +1.13% | |
| Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema | Press release | GlobeNewswire | +1.02% | +2.21% | |
| Oculis to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.50% | +0.92% | |
| Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis | Press release | GlobeNewswire | +4.14% | +6.83% | |
| Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting | Press release | GlobeNewswire | +0.66% | +1.68% | |
| Oculis to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.78% | -2.08% | |
| Form 20-F Oculis Holding AG For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.78% | -2.08% | |
| Form 6-K Oculis Holding AG For: Mar 04 | SEC filing · Form 6-K | SEC EDGAR | -0.78% | -2.08% | |
| Form F-3ASR Oculis Holding AG | SEC filing · Form F-3ASR | SEC EDGAR | -0.78% | -2.08% | |
| Form 6-K Oculis Holding AG For: Mar 03 | SEC filing · Form 6-K | SEC EDGAR | +4.10% | +0.54% | |
| Oculis Appoints Katie Kazem as Chief Legal Officer | Press release | GlobeNewswire | +0.14% | +0.70% | |
| Form EFFECT Oculis Holding AG | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.10% | |
| Form POS AM Oculis Holding AG | SEC filing · Form POS | SEC EDGAR | -1.47% | -5.64% | |
| Form 6-K Oculis Holding AG For: Nov 10 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.51% | |
| Form F-3 Oculis Holding AG | SEC filing · Form F-3 | SEC EDGAR | +0.00% | -0.51% | |
| Oculis to Participate in Upcoming November Investor Conferences | Press release | GlobeNewswire | +0.00% | +0.31% | |
| Form 6-K Oculis Holding AG For: Oct 31 | SEC filing · Form 6-K | SEC EDGAR | -1.45% | +1.04% | |
| Form 6-K Oculis Holding AG For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | -4.46% | -8.60% | |
| Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 | Press release | GlobeNewswire | -0.28% | +2.18% | |
| Form 6-K Oculis Holding AG For: Oct 06 | SEC filing · Form 6-K | SEC EDGAR | -0.05% | -0.99% | |
| Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy | Press release | GlobeNewswire | +0.78% | +3.89% | |
| Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS | Press release | GlobeNewswire | — | +4.29% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OCS section they belong to.
Where else OCS is measured.
OCS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oculis Holding AG's median reaction calculated?
Every labeled OCS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 322 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of OCS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OCS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.